Lexeo Therapeutics Inc. Financials
LXEO
All currency values in $ millions unless otherwise noted
| Income Statement | DEC 2025 ~1.7:1 split | DEC 2024 6:1 split | DEC 2023 ~3.3:1 split | DEC 2022 |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | – | – | – | $1 |
| General & Administrative | $45 | $32 | $15 | $12 |
| Research & Development | $64 | $74 | $53 | $49 |
| Total Operating Expenses | $109 | $106 | $69 | $61 |
| Operating Income | -$109 | -$106 | -$69 | -$61 |
| Non-Operating | ||||
| Net Interest Expense | $6 | $7 | $3 | $1 |
| Other Non-Operating Income (Expense) | $4 | -$0 | -$1 | -$0 |
| EBT (Earnings Before Tax) | -$100 | -$98 | -$66 | -$59 |
| Income Tax Expense | $0 | $0 | – | – |
| Net Income | ||||
| Net Income | -$100 | -$98 | -$66 | -$59 |
| Per Share Data | ||||
| Revenue Per Share | – | – | – | $0.40 |
| EPS (Basic) | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| EPS (Diluted) | -$1.86 | -$3.09 | -$12.40 | -$36.36 |
| Weighted Avg Shares (Basic) | 53.6M | 31.8M | 5.4M | 1.6M |
| Weighted Avg Shares (Diluted) | 53.6M | 31.8M | 5.4M | 1.6M |
| Shares Outstanding | 53.6M | 31.8M | 5.4M | 1.6M |
Lexeo Therapeutics (LXEO) financials: revenue, profit and margins
Lexeo Therapeutics (LXEO) generated about n/a in revenue and -$105 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Lexeo Therapeutics profitable?+
Lexeo Therapeutics reported about -$105 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 12 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 16 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with LXEO
Held by ETFs
LXEO is in 14 US ETFs. The largest of them, with LXEO's weight in each:
iShares Russell 2000 Value ETFIWN0.01%of the fund
State Street SPDR S&P Biotech ETFXBI0.05%of the fund
iShares Biotechnology ETFIBB0.01%of the fund
Fidelity Enhanced Small Cap ETFFESM0.01%of the fund
State Street SPDR S&P Kensho New Economies Composite ETFKOMP0.07%of the fund
iShares Micro-Cap ETFIWC0.05%of the fund
Spot a number that looks wrong? Check it in LXEO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LXEO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.